The field of CAR-T cell therapy development has experienced significant growth over the past ten years, resulting in the regulatory approval and marketing of six new therapies for hematologic malignancies. The remarkable response rates observed in clinical settings for acute lymphoblastic leukemia and non-Hodgkin lymphoma and the rapid approval of these therapies based on pivotal phase 2 clinical data have been the primary source of excitement regarding these developments.
The technologies around CAR-T cell development have been changing rapidly, and the need for improvements in the functionality of the cells is critical. Despite the spectacular responses observed in heme malignancies, the function of CAR-T cells in the solid tumor setting has not kept pace. Further enhancements and the ability to evaluate the functionality of the T cells are crucial to identify functions that will facilitate their implementation across many cancer types.
This Methods Collection aims to explore established methods for understanding CAR-T cell characterization and functions, including signal transduction, tonic signaling, metabolism, secretion of cytokines, potency, serial killing, scRNA-Seq analysis, genome editing, and others. Implementing these methods will contribute to a better understanding of the diverse and multifunctional population dynamics of CAR-T cells, potentially leading to improvements that enhance their effectiveness across multiple cancer types.
0 Views
•
Cited by 1
•
2024
•
1Institutes of Biomedical Sciences, Fudan University, 2Clinical Center of Biotherapy at Zhongshan Hospital, Fudan University, 3Department of Oncology and Bio-therapeutic Center, Shenzhen Third People's Hospital, Southern University of Science and Technology, 4Shanghai Public Health Clinical Center, Fudan University
Functional verification of hypoxia-sensitive CAR-T cells
Chen Zhao*1
1Shanghai Public Health Clinic Center & Institutes of Biomedical Sciences, Fudan University
Preclinical assessment of academic CAR T cells for acute myeloid leukemia
Ciprian Tomuleasa*1
1Iuliu Hațieganu University of Medicine and Pharmacy|Ion Chiricuta Oncology Institute
Identification of Cas9 and Cas12a Off-Targets Using an Improved SITE-Seq® Assay
Finey Ruan1,
Arthur Owen1,
Beatitude Steffen1,
Jack Taylor1,
Scott Gradia1,
Eric Stawiski1,
Matthew Thompson*1
1Caribou Biosciences, Inc.
Optimizing CAR-NK Cell Transduction and Expansion: A Protocol Leveraging Cytokine Modulation for Enhanced Performance.
Tiziano Ingenere1,
Suman Mitra1,
Silvia Gaggero*1
1INSERM, University of Lille